Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity.
Steroid refractory graft versus host disease (GVHD) presents a significant therapeutic challenge due to the limited efficacy and safety of second-line treatments. Three patients with extensively pretreated, refractory GVHD were treated with a targeted anti-T-cell agent, alefacept, and demonstrated rapid and clinically significant improvement in their GVHD, facilitating tapering of corticosteroids. The pathological and immunohistochemical findings of GVHD also improved, validating our clinical impression. These preliminary findings indicate that alefacept may have beneficial activity in GVHD warranting further study.
Published In/Presented At
Toor, A. A., Stiff, P. J., Nickoloff, B. J., Rodriguez, T., Klein, J. L., & Gordon, K. B. (2007). Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity. The Journal of dermatological treatment, 18(1), 13–18. https://doi.org/10.1080/09546630601121045
Medicine and Health Sciences
Department of Medicine, Hematology-Medical Oncology Division